BBS-Bioactive Bone Substitutes Plc announced a strategic leadership transition, appointing Juliusz Rakowskias the new Chief Executive Officer (CEO), effective 3 November 2023. The Company and the current CEO Ilkka Kangasniemi have mutually agreed that he will continue to offer his insights and expertise to the company in an advisory capacity. The appointment signifies the company's on-going transition from research and development to a commercial phase, as the approval of the CE marking of the Company's first product (ARTEBONE® Paste) is expected during Q2/2024.

Juliusz Rakowski brings a strong track record of leadership and a deep understanding of product sales processes in the life science industry to BBS. With over 15 years of commercial experience in relevant industry roles, he is poised to lead BBS into its next phase of product launch, building the distribution network and market expansion.